A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier

• DOI: 10.2147/ijn.s258316
• Publication Date: 2021-02-12T14:02:55Z
• Authors: Hui Ye; Xiaoying Chu; Zhensheng Cao; Xuanxuan Hu; Zihan Wang; Meiqi Li; Leyu Wan; Yongping Li; Yongge Cao; Zhanqiu Diao; Fengting Peng; Jinsong Liu; Lihua Xu
• Keywords: Medicine (General); cervical cancer; Mice, Nude; antisense lncrna of mdc1; Apoptosis; Cell Cycle Proteins; 03 medical and health sciences; R5-920; Drug Delivery Systems; International Journal of Nanomedicine; Cell Movement; Cations; Cell Line, Tumor; Animals; Humans; Molecular Targeted Therapy; Original Research; Adaptor Proteins, Signal Transducing; Cell Proliferation; Drug Carriers; Mice, Inbred BALB C; 0303 health sciences; Magnetic Phenomena; oxaliplatin; targeted therapy; 3. Good health; Gene Expression Regulation, Neoplastic; Oxaliplatin; Drug Liberation; Liposomes; magnetic thermosensitive cationic liposome; Female

Background: This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA MDC1 (MDC1-AS) Cervical cancer cells evaluate efficiency this its antitumor effects on cancer. Methods: Thermosensitive liposomes were prepared using thin-film hydration method. The OXA MDC1-AS vectors loaded into system, in vitro release activity, regulating MDC1, cytotoxicity, vivo activity determined. Results: system had desirable targeted delivery efficacy, release, MDC1. Codelivery enhanced inhibition cervical cell growth vivo, compared with single delivery. Conclusion: can be applied combined chemotherapy gene therapy Keywords: liposome, oxaliplatin, therapy,